75104-96-0

Basic information

• Product Name: 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine
• CAS NO: 75104-96-0
• Molecular Weight: 257.154
• Mol File: 75104-96-0.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine(75104-96-0)
• EPA Substance Registry System: 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine(75104-96-0)

Safety Data

• Hazardous Substances Data: 75104-96-0(Hazardous Substances Data)

Usage

Description

6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine is a chemical compound belonging to the benzothiazole family. It is characterized by the presence of a bromine atom at the 6th position, and two methyl groups attached to the nitrogen atoms. 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine exhibits unique chemical and biological properties, making it a potential candidate for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine is used as a therapeutic agent for the treatment or prevention of tau aggregate disorders. Tauopathies are a group of neurodegenerative diseases characterized by the abnormal accumulation of tau protein aggregates in the brain, leading to neuronal dysfunction and cell death. 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine may exert its therapeutic effects by modulating the aggregation process of tau proteins, thereby reducing their toxic effects on neurons and slowing down the progression of the disease.
In addition to its potential use in treating tau aggregate disorders, 6-bromo-N,N-dimethylbenzo[d]thiazol-2-amine may also find applications in other areas of the pharmaceutical industry, such as in the development of new drugs targeting other neurodegenerative diseases or as a chemical intermediate in the synthesis of other bioactive compounds.

Upstream product

• 137-26-8 Thiram 
• 562080-91-5 N-(4-bromo-2-iodophenyl)acetamide 
• 66416-72-6 4-bromo-2-iodoaniline 
• 128-04-1 sodium N,N-dimethyldithiocarbamate dihydrate 
• 128-04-1 sodium dimethyldithiocarbamate 
• 615-57-6 2,4-dibromo-aniline 
• 16906-70-0 phenyl N,N-dimethyl dithiocarbamate 
• 38762-41-3 2-chloro-4-bromoaniline 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 
• 1985-12-2 4-Bromophenyl isothiocyanate 
• 67-66-3 chloroform 
• 705-62-4 N,N-dimethyl-N'-phenylthiourea 
• 75105-07-6 N_⁽¹⁾-(4-bromophenyl)-N,N-dimethylthiourea 
• 80945-86-4 6-bromo-2-chloro-benzothiazole 

Relevant articles and documents

PI3Kalpha selective inhibitor and preparation method and application thereof

The invention discloses a PI3Kalpha selective inhibitor and a preparation method and application thereof, a triazine ring benzoxazole compound and a preparation method and application thereof, and the structural formula of the compound is shown as a formula I or a pharmaceutically acceptable salt thereof. Biochemical activity tests show that the compounds have good inhibitory activity on PI3K alpha, so that the compounds can provide effective inhibitors with better selectivity for treatment of diseases regulated by PI3K, and target drugs for treating diseases related to PI3K signal pathways, such as gastric cancer, breast cancer, ovarian cancer and leukemia, are expected to be developed.

Intermediate compound as well as preparation method and application thereof

The invention discloses an intermediate compound as well as a preparation method and application thereof. The synthesized intermediate compound is used for preparing targeted anti-cancer drugs, such as CDK4, CDK6, DYRK2 and other inhibitors, and is used for preventing and/or treating cancers or tumor related diseases including breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The intermediate compound is simple in preparation condition, high in reaction yield and stable in performance.

1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).